hanieh barghchi

Nowadays, improving anxiety, depression, and stress is important in managing non-alcoholic fatty liver (NAFLD). Thus, this study aimed to evaluate eight weeks of pomegranate peel (PP) supplementation on depression, anxiety, and stress scale changes among NAFLD patients.  This randomized clinical trial was conducted on 76 NAFLD patients assigned to the PP (n=39) or placebo (n=37) groups. Participants received the pomegranate peel (1500 mg/day) or placebo for eight weeks. PP capsules were prepared fromdry extract of PP by soaking. A diet with reduced calorie intake and healthy recommendations was given to all participants. The status of NAFLD was checked with two-dimensional elastography. Mental health was evaluated using depression, anxiety, and stress scale, and dietary intake was assessed by 3-day recall before and after the intervention.  The average age of the participants was 43.1±8.6 years, of whom 51.3% were women. In the PP group, weight, liver stiffness, and hepatorenal sonography index changes significantly differed from the placebo group before and after adjusting potential covariates, including weight and physical activity (P< 0.001). Depression and stress scores changed significantly in the PP group during the study before and after adjusting potential covariates (P= 0.002, 0.05, respectively). Anxiety score changes were insignificant between the two groups (P= 0.1).  Based on the results, eight-week supplementation of pomegranate peel ameliorated depression and stress symptoms among NAFLD patients.

Non-alcoholic fatty liver disease (NAFLD) is a serious public health issue. Even though various natural and synthetic therapies are in the advanced stages of development, there is no authorized therapy for NAFLD. The use of anti-oxidant and anti-inflammatory compounds is one of these natural treatments. Portulaca oleracea aerial parts' extracts have shown various pharmacological properties, including antioxidant, anti-inflammatory, and liver protection due to alkaloid compounds, flavonoids, terpenoids, sterols, omega-3 unsaturated fatty acids, and many vitamins and minerals.

We intend to examine the effectiveness of Portulaca oleracea extract in improving the symptoms caused by NAFLD.

A randomized, double-blinded, controlled, parallel clinical trial is designed to study the effects of P. oleracea supplementation on the clinical and paraclinical findings in patients with NAFLD. An intervention group will get 700 mg of P. oleracea supplementation for eight weeks, while a control group will receive a placebo. Throughout the intervention, the clinical and nutritional status will be assessed three times. At the 0, 30, and 60th days of the intervention, anthropometric evaluation, blood pressure, and gastrointestinal problems will be monitored. Transient elastography will be done at the start and end of the research to assess the liver state. In addition, an International Physical Activity Questionnaire (IPAQ) and a 3-day food record will be collected, as well as biochemical variables, such as CBC-diff (complete blood count with differential count), lipid profiles, FBS, Fasting Blood Sugar; serum insulin, hepatic-related parameters, namely enzymes [ALP (alkaline phosphatase), AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gamma-glutamyl transferase)], total and direct bilirubin, and inflammatory [hs-CRP (C-reactive protein), ESR (erythrocyte sedimentation rate) and IL-6 (interleukin-6)] and oxidative stress markers [SOD (super oxide dismutase), GSH-Px (glutathione peroxidase) and MDA (malondialdehyde)].

This is the first randomized clinical trial (RCT) protocol specifically created for patients with NAFLD to evaluate the impact of P. oleracea supplementation. We intend to demonstrate that the suggested procedure is a novel and effective approach to decreasing NAFLD's laboratory and clinical symptoms. We also expect that supplementation with 700 mg of P. oleracea for 60 days will improve liver steatosis and clinical and nutritional status and reduce NAFLD patients' inflammation and oxidative stress.

Nonalcoholic fatty liver disease (NAFLD) is a health problem growing in line with the rising prevalence of obesity in children and adolescents, which may be correlated with different metabolic abnormalities such as osteoporosis.

This study aimed to evaluate the possible relationship between NAFLD with body composition and bonemineral density (BMD) in obese and overweight adolescents.

This cross-sectional study encompassed 70 adolescents aged 11 - 18 years and was conducted during March 2016 and September 2016 in Mashhad, Iran. Anthropometric parameters and blood biomarkers were measured. Fat mass, fat-free mass, and BMD were determined using dual-energy X-ray absorptiometry (DXA) scans, and NAFLD was also assessed using Fibroscan. All statistical data were analyzed using SPSS software version 21. Multivariate linear regression assessed the relationship between liver fat content with bone-related indicators, andmultivariate logistic regression detected the relationship between body composition and NAFLD.

Total and trunk fat mass were significantly correlated with higher NAFLD even after controlling for intervening factors (total fat mass, OR = 1.27; 95% CI, 1.016 to 1.59, P = 0.036; trunk fat mass, OR = 1.35; 95% CI, 0.97 to 1.88, P = 0.045). Moreover, liver fat content was significantly correlated with lower BMD Z-score after adjusting for gender, BMI Z-score, ALT, fat mass index, total lean mass, and physical activity (β = -0.285, P = 0.048).

The findings of the present study suggest that excess adipose tissue is correlated with higher NAFLD. Moreover, liver steatosis may be correlated with decreased BMD Z-score in overweight/obese adolescents.